Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)FDA Approves Nonopioid Combination Therapy for Postoperative Pain

Combogesic IV consists of acetaminophen 1000mg and ibuprofen 300mg in a solution for IV infusion.

In a significant development for postoperative pain management, the FDA has given its approval for a non-opioid combination therapy. This marks a crucial step in addressing the need for effective and safer alternatives to opioid-based pain relief.

Key Points

  • The FDA-approved therapy is known as Combogesic IV, or Maxigesic IV outside the US.
  • Combogesic IV is an intravenous formulation of acetaminophen (1000mg) and ibuprofen (300mg).
  • The approval was backed by data from two phase 3 studies evaluating its effects on adults with postoperative pain.
  • Results showed a faster onset of action and greater pain relief with Combogesic IV compared to ibuprofen IV or acetaminophen IV alone.
  • Treatment with Combogesic IV was also associated with reduced opioid consumption.
  • The therapy was found to be safe and well-tolerated in a safety study involving 232 patients undergoing general, orthopedic, or plastic surgery.
  • Distribution of the product in US hospitals is expected to begin in early 2024.

“The greatest evil is physical pain.”
– Saint Augustine

More on Pain Management

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form